Preimplantation Genetic Testing Market - Global Forecast 2025-2032

The preimplantation genetic testing market is evolving rapidly as it increasingly shapes clinical practice, supply chain resilience, and R&D priorities for fertility specialists and laboratory executives. This report provides a clear, data-backed view of the market, addressing the technological, regulatory, and commercial forces senior leaders need to navigate.

Market Snapshot: Preimplantation Genetic Testing Market Growth and Outlook

The preimplantation genetic testing market expanded significantly from USD 780.19 million in 2024 to USD 873.74 million in 2025, maintaining momentum with a projected CAGR of 12.55%. The market is expected to reach USD 2.00 billion by 2032, supported by advancing genomic diagnostics, increased adoption in fertility clinics, and evolving reimbursement frameworks. Senior decision-makers will find actionable insights on market sizing, dynamic trends, and future market scenarios.

Comprehensive Scope & Segmentation

• Testing Type: PGT-A (Aneuploidy), PGT-M (Monogenic Disorders), PGT-SR (Structural Rearrangements)
• Test Type: Preimplantation Genetic Diagnosis, Preimplantation Genetic Screening
• Technology Type: Comparative Genomic Hybridization, Fluorescent In-Situ Hybridization, Next-Generation Sequencing, PCR-Based Testing, Single-Nucleotide Polymorphism
• Offering: Instruments, Reagents & Consumables, Software
• End User: Diagnostic Laboratories, Fertility Clinics, Hospitals, Research Institutes
• Regions Covered: Americas (North America: United States, Canada, Mexico; Latin America: Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (Europe: United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland; Middle East: United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel; Africa: South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Notable Companies: Abbott Laboratories, Agilent Technologies, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, Yikon Genomics (Shanghai) Co., Ltd.

Key Takeaways for Senior Executives

• Collaboration across scientists, fertility experts, and genetic counselors is strengthening quality control, leading to better clinical outcomes and reinforcing the importance of teamwork in diagnostic processes.
• Integration of artificial intelligence into embryo assessment delivers a new layer of precision, supporting differentiated offerings for clinics prioritizing advanced selection protocols.
• Regional growth is shaped by policy shifts and healthcare modernization, with Asia Pacific gaining momentum through biotech investments and Europe influenced by regulatory complexity and emerging best practices.
• Partnerships and acquisitions are enabling companies to streamline supply chains and accelerate innovation, directly impacting competitive positioning and market access strategies.
• Demand is diversifying, requiring stakeholders to fine-tune offerings for centralized labs, specialist clinics, hospitals, and research settings, driven by varying regulatory standards and patient needs.

Tariff Impact: Navigating US Trade Policies in Preimplantation Genetic Testing

New United States trade tariffs in 2025 have altered procurement for labs and distributors, leading to shifts in sourcing strategies and local manufacturing partnerships. The industry now places greater emphasis on inventory buffers and supplier diversification to protect against potential supply interruptions. Senior leaders must monitor ongoing tariff developments and seek resilient collaborations with domestic vendors to maintain cost control and service reliability.

Methodology & Data Sources

This research applies a rigorous methodology, utilizing structured interviews with clinical experts, policy authorities, and laboratory executives. Key data is further validated using peer-reviewed literature, regulatory filings, and device approval records. Quantitative insights are cross-checked with assay performance metrics, and qualitative trends are extracted through systematic thematic analysis. The approach ensures robust, unbiased findings and transparent scenario evaluation.

Why This Report Matters

• Delivers strategic clarity for product differentiation, procurement alignment, and expansion planning based on proven market and segment insights.
• Equips decision-makers with up-to-date analysis on regional adoption dynamics, tariff consequences, and innovation roadmaps, supporting informed resource allocation.
• Provides an evidence-based foundation for stakeholder engagement, regulatory compliance, and partnership strategy in the highly regulated fertility sector.

Conclusion

Preimplantation genetic testing is redefining assisted reproduction and laboratory diagnostics. Leaders adopting a data-driven, partnership-oriented approach will be best positioned to realize operational efficiency and sustainable growth as the market matures.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.